Berenberg hikes AstraZeneca target price, eyes product launches

Alexander Bueso Sharecast | 20 Mar, 2017 12:52 - Updated: 12:52 | | |

astrazeneca

AstraZeneca

5,152.00

17:25 21/07/17
0.57%
29.00
  • 7,452.91
  • -0.47%-34.96
  • Max: 7,515.12
  • Min: 7,433.89
  • Volume: 0
  • MM 200 : n/a
17:25 21/07/17
  • 3,529.83
  • -0.08%-3.00
  • Max: 3,548.22
  • Min: 3,516.80
  • Volume: 0
  • MM 200 : n/a
17:25 21/07/17
  • 1,492.38
  • -1.04%-15.69
  • Max: 1,511.17
  • Min: 1,488.76
  • Volume: 0
  • MM 200 : n/a
17:30 21/07/17
  • 13,961.69
  • 0.33%45.56
  • Max: 13,996.90
  • Min: 13,916.13
  • Volume: 0
  • MM 200 : n/a
17:30 21/07/17
  • 4,134.24
  • -0.40%-16.50
  • Max: 4,164.83
  • Min: 4,122.78
  • Volume: 0
  • MM 200 : n/a
17:30 21/07/17
  • 4,079.62
  • -0.38%-15.45
  • Max: 4,108.53
  • Min: 4,068.40
  • Volume: 0
  • MM 200 : n/a
17:18 21/07/17

Analysts at Berenberg pushed up their target price on AstraZeneca in anticipation of multiple blockbuster launches and lessened competitive headwinds from generics in 2017.

By year-end, the impact from its patent expiries should also have dropped out from the annual comparisons, the German broker said in a research note published on Monday but dated 17 March.

Analysts Alistair Campbell, Joseph Lockey and Laura Sutcliffe PhD bumped up their target from 4866p to 5670p and reiterated a 'Buy' recommendation.

Dominating the outlook for the company in the very short-term were its immuno-oncology (IO) drug, Durvalumab, and its first-line lung cancer drug trial, MYSTIC.

The latter marked an important milestone, the analysts said, with lung cancer potentially adding $2.5bn of sales; nevertheless, although it was not essential for the drugmaker's turnaround it had a reasonable chance of success, they said.

Should MYSTIC fail, Berenberg's discounted cash-flow models pointed to a share price value of 5158p.

"This does not offer much upside from current levels, but also implies that MYSTIC expectations are not aggressively high. If we assume MYSTIC success, and remove our risk weighting entirely, our DCF climbs to £59.19, giving 22% upside from current levels."

Astra's pipeline and current launches might add $10.0bn to the topline, with IO accounting for a quarter of that.

When risk-weighted, that pipeline would help the London-based frim grow sales at a yearly clip of 8% between 2017 and 2023.

The firm would also be able to rein in cost growth , helping margins to recover and driving EPS gains per annum of 28%, they said.

EBIT margins were seen recovering from 17.5% in 2017 top 20.7% in 2018 and 25.1% for 2019. In 2016 they clocked in at 29.2%.

More news

19:01 Commodities: Increasing supply of oil weighs heavy on the market

An over supply of crude from Nigeria and Libya of approximately 1m barrels per day weighed heavily on the oil market on Friday with September contracts for both WTI crude and Brent crude down 2.28% and 2.29% respectively.

18:58 Magnolia Petroleum announces divestment of North Dakota and Oklahoma wells

Magnolia Petroleum, an Oklahoma based oil and gas investment company, has divested and agreed farmouts over several wells in North Dakota and Oklahoma for a total of $411,000.

18:55 Europe close: DAX dives on euro peaks and colluding carmakers

European stocks ended the week firmly in the red as the euro continued to march higher, with the strength in the single currency weighing on exporters and car makers were hit by reports of collusion in the industry, combining to send the Dax to new three-month lows.

18:34 FX round-up: Lack of data release makes way for indecisive Cable moves

On Friday sterling managed to recover most of its losses against the US dollar from prior session posting a morning high of 1.3020, only managing to touch psychological resistance of 1.3000 briefly.

17:29 London close: FTSE profit taking kicks shares into red

UK stocks were lacklustre on Friday as oil and stocks plunged but investors mulled yet more waxing and waning of Brexit negotiations, proving that uncertainty is the only certainty surrounding the issue.

17:07 FTSE 100 movers: Paddy Power leads Friday retreat

London's FTSE 100 was in the red on Friday, along with stock benchmarks in Europe and the US.

16:36 General Electric tumbles further as profits slide

US industrial giant General Electric reported net profits of $1.34bn for the second quarter of 2017, 53% less than its earnings for the same quarter in 2016.

16:25 US open: Wall Street slips amid weak tech earnings, downbeat GE

Wall Street was slightly lower in early trading following disappointing updates from Microsoft and Ebay, alongside weak guidance from industrial conglomerate GE.

16:03 Catalyst Media softens blow from failed Greyhound track bids

Retail betting service supplier Sports Information Services (SIS), in which Catalyst Media Group holds a 20.5% stake, has secured rights and media agreements for its greyhound and horseracing content.

16:00 Dalata buys Hotel La Tour for £31m

AIM-listed Dalata has acquired Hotel La Tour for £31m from Hotel La Tour Limited, which owns the long leasehold interest in the hotel situated on Park Street in the centre of Birmingham.